UPPSALA, SWEDEN / ACCESSWIRE / May 21, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) In a new clinical study published in the high-impact Anesthesiology journal, a team of US-based researchers compared the accuracy and precision of commercially available neuromuscular block monitors. The study confirms the leading accuracy and precision of Senzime's TetraGraph system, which produced results similar to a gold-standard laboratory reference, while the conventional AMG-based monitors have substantial variability and imprecision that could be clinically significant..

瑞典乌普萨拉/ACCESSWIRE/2024年5月21日/Senzime（STO:SEZI）（OTCQX:SNZZF）在《高影响力麻醉学杂志》上发表的一项新的临床研究中，一组美国研究人员比较了市售神经肌肉阻滞监测仪的准确性和精密度。该研究证实了Senzime的TetraGraph系统的领先准确性和精密度，该系统产生的结果类似于金标准实验室参考，而传统的基于AMG的监护仪具有很大的可变性和不精确性，可能具有临床意义。。

Recently published guidelines and recommendations by ASA (American Society of Anesthesiologists) and ESAIC (European Society of Anaesthesiology and Intensive Care) have called for routine use of quantitative neuromuscular monitoring to prevent residual neuromuscular block. There are currently two types of neuromuscular block monitors on the market that conform to these guidelines: acceleromyography (AMG)- and electromyography (EMG)-based monitors..

ASA（美国麻醉医师学会）和ESAIC（欧洲麻醉学和重症监护学会）最近发布的指南和建议呼吁常规使用定量神经肌肉监测来预防残留的神经肌肉阻滞。目前市场上有两种类型的神经肌肉阻滞监护仪符合这些指南：基于加速度描记术（AMG）和肌电图（EMG）的监护仪。。

The study, 'Accuracy and Precision of Three Acceleromyographs, Three Electromyographs and a Mechanomyograph Measuring the Train-of-Four Ratio in the Absence of Neuromuscular Blocking Drugs' by Wedemeyer Z et al. was designed to compare three commercially available AMG monitors and three EMG-based monitors, to a laboratory gold-standard mechanomyograph (MMG)..

Wedemeyer Z等人的研究“在没有神经肌肉阻滞剂的情况下，测量四列比率的三个加速度计，三个肌电图和一个机械肌描记器的准确性和精密度”旨在将三个市售的AMG监测仪和三个基于EMG的监测仪与实验室金标准机械肌描记器（MMG）进行比较。。

The study concluded that the AMG-based monitors produced overshoot of measurements and had substantial variability in the data that could be clinically significant. Senzime's EMG-based TetraGraph-system was shown to measure the responses with minimal overshoot and variability, in line with the gold-standard MMG reference technique.

该研究得出的结论是，基于AMG的监护仪产生了测量的超调量，并且数据的差异很大，可能具有临床意义。根据金标准MMG参考技术，Senzime基于肌电图的TetraGraph系统可以以最小的超调和变异性来测量响应。

'This is an important, high-impact study that confirms the leading accuracy and precision of EMG as well as our TetraGraph system. This study may well solidify the role of the EMG-based TetraGraph as the new clinical standard, and certainly confirms what should be the preferred monitoring system for hospitals that are conforming to the new guidelines,' comments Philip Siberg, CEO of Senzime..

“这是一项重要的，高影响力的研究，证实了肌电图以及我们的四联图系统的领先准确性和精确度。Senzime首席执行官菲利普·西贝格（PhilipSiberg）评论说，这项研究很可能巩固基于肌电图的四联图作为新临床标准的作用，并肯定了符合新指南的医院首选的监测系统应该是什么。。

AMG utilizes an accelerometer to measure the acceleration of muscle contraction in response to nerve stimulation. Important limitations of AMG include its time-consuming calibration procedure, reported variability and overshoot of data, and limitations of use in certain surgeries when free movement of the monitored muscle (thumb) cannot be assured.

AMG利用加速度计测量响应神经刺激的肌肉收缩加速度。AMG的重要局限性包括其耗时的校准程序，报告的数据变异性和超调，以及在无法确保受监测肌肉（拇指）自由运动时在某些手术中的使用限制。

EMG differs as uses a disposable sensor and advanced algorithms that measure events at the neuromuscular junction - where the drugs work. The use of a disposable sensor to measure electrical activity is very precise and does not require the patient's thumb to move freely, hence eliminating many of the limitations of AMG technology..

肌电图的不同之处在于使用一次性传感器和先进的算法来测量药物工作的神经肌肉接头处的事件。使用一次性传感器测量电活动非常精确，不需要患者的拇指自由移动，因此消除了AMG技术的许多局限性。。

For further information, please contact:

欲了解更多信息，请联系：

Philip Siberg, CEO of Senzime AB

Philip Siberg，Senzime AB首席执行官

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

电话：+46（0）707 90 67 34，电子邮件：philip.siberg@senzime.com

About Senzime

关于Senzime

Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery.

Senzime总部位于瑞典，是一家领先的医疗器械公司，开发、制造和销售经CE和FDA批准的患者监测系统。该公司提供了一系列创新的解决方案，包括TetraGraph®和ExSpiron®2Xi，用于准确监测神经肌肉和呼吸功能，通常在手术前后。

The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures..

目标是帮助消除院内并发症，并从根本上降低与外科手术和高视力手术相关的医疗保健成本。。

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX:SNZZF). More information is available at senzime.com ..

Senzime的目标是每年创造价值超过400亿瑞典克朗的市场机会，并与全球领先市场的销售团队合作。该公司股票在纳斯达克-斯德哥尔摩主要市场（纳斯达克：SEZI）上市，并在美国OTCQX市场（OTCQX：SNZZF）交叉交易。更多信息请访问senzime.com。。

Attachments

附件

New clinical study published in Anesthesiology confirms the leading accuracy and precision of Senzime's TetraGraph system

发表在《麻醉学》上的一项新的临床研究证实了Senzime四联图系统的领先准确性和精确性

SOURCE: Senzime

来源：敏感

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿